SARS-CoV-2-infection-and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
K Srivastava, JM Carreño, C Gleason, B Monahan… - Immunity, 2024 - cell.com
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies …
syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies …
Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the Omicron variants: A retrospective cohort study …
S Ono, N Michihata, H Yamana… - Clinical Infectious …, 2023 - academic.oup.com
Background Direct comparative effectiveness of booster doses of BNT162b2 and mRNA-
1273 after BNT162b2 primary vaccination is unknown. Methods We investigated …
1273 after BNT162b2 primary vaccination is unknown. Methods We investigated …
COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the …
VG Hall, BW Teh - The Journal of infectious diseases, 2023 - academic.oup.com
Patients with cancer demonstrate an increased vulnerability for infection and severe disease
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …
SARS-CoV-2 in immunocompromised individuals
S DeWolf, JC Laracy, MA Perales, M Kamboj… - Immunity, 2022 - cell.com
Immunocompromised individuals and particularly those with hematologic malignancies are
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …
Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study
Background Patients with primary and secondary antibody deficiency are vulnerable to
COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine …
COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine …
Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination
M Yoshida, Y Kobashi, T Kawamura, Y Shimazu… - Scientific reports, 2023 - nature.com
The objective of this study was to clarify the impact of adverse reactions on immune
dynamics. We investigated the pattern of systemic adverse reactions after the second and …
dynamics. We investigated the pattern of systemic adverse reactions after the second and …
Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians
S Rakshit, S Babji, C Parthiban, R Madhavan, V Adiga… - npj Vaccines, 2023 - nature.com
Detailed characterisation of immune responses induced by COVID-19 vaccines rolled out in
India: COVISHIELDTM (CS) and COVAXIN®(CO) in a pre-exposed population is only …
India: COVISHIELDTM (CS) and COVAXIN®(CO) in a pre-exposed population is only …
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
XJ Wang, L Yao, HY Zhang, KL Zhu, J Zhao, BD Zhan… - Genome Medicine, 2022 - Springer
Background The emergence of SARS-CoV-2 Omicron subvariants has raised questions
regarding resistance to immunity by natural infection or immunization. We examined the …
regarding resistance to immunity by natural infection or immunization. We examined the …
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
COVID-19 pandemic has been managed through global vaccination programs. However,
the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus …
the antibody waning in various types of vaccines came to notice. Hereby, PastoCovac Plus …
Impact of sex and age on vaccine-related side effects and their progression after booster mRNA COVID-19 vaccine
M Mori, A Yokoyama, A Shichida, K Sasuga… - Scientific Reports, 2023 - nature.com
In mRNA COVID-19 vaccination, side effects after the first and second dose have been well
reported. However, studies about side effects after booster vaccine are sparse. 272 …
reported. However, studies about side effects after booster vaccine are sparse. 272 …